{"result": "(\"entity\"<|>FIBROBLASTOS<|>ORGANIZATION<|>Fibroblasts are a type of cell found in connective tissue, which were used in studies by Rizzo et al to understand the effects of fatty acids in patients with ALD.)\n##\n(\"entity\"<|>ÁCIDO OLEICO<|>ORGANIZATION<|>Oleic acid is a monounsaturated fatty acid that was added to fibroblast cultures to reduce levels of C26:0 in patients with ALD.)\n##\n(\"entity\"<|>ÁCIDO ERÚCICO<|>ORGANIZATION<|>Erucic acid is a fatty acid present in rapeseed and mustard oils, which patients with ALD cannot metabolize.)\n##\n(\"entity\"<|>DIETA<|>EVENT<|>The diet designed for ALD patients includes restrictions on saturated very long-chain fatty acids and incorporates GTO and GTE for treatment.)\n##\n(\"entity\"<|>NIVEL PLASMÁTICO<|>EVENT<|>Plasma levels refer to the concentration of C26:0 in the blood, which is a key measure in the management of ALD.)\n##\n(\"relationship\"<|>FIBROBLASTOS<|>ALD<|>Fibroblasts from patients with ALD were used in studies to understand the impact of dietary fatty acids<|>6)\n##\n(\"relationship\"<|>ÁCIDO OLEICO<|>ALD<|>Oleic acid was shown to reduce C26:0 levels in fibroblasts from ALD patients<|>7)\n##\n(\"relationship\"<|>ÁCIDO ERÚCICO<|>ALD<|>Erucic acid is a fatty acid that cannot be metabolized by ALD patients, influencing dietary treatment strategies<|>6)\n##\n(\"relationship\"<|>DIETA<|>ALD<|>The diet for ALD patients is specifically designed to manage the condition by controlling fatty acid intake<|>8)\n##\n(\"relationship\"<|>NIVEL PLASMÁTICO<|>ALD<|>Plasma levels of C26:0 are critical indicators of the severity of ALD and the effectiveness of dietary interventions<|>9)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de los ácidos grasos que se encuentran en la mitocondria y en los microsomas. Los estudios que demostraron la contribución de los lípidos de la dieta en el acúmulo anómalo de AGCML llevaron al diseño de dietas muy restringidas en AGCML saturados11-12. No obstante, estudios subsiguientes pudieron demostrar que la gran mayoría del ácido hexacosanoico (C26:0) que se acumula en la ALD deriva de la síntesis endógena, ya que el tejido nervioso posee el sistema de elongación de los ácidos grasos, y este sistema es más activo en el tejido nervioso de los pacientes con ALD que en los controles sanos13. De hecho, en la ALD, la restricción severa de AGCML saturados (menos de 3 mg/día de C26:0, en comparación con 12-40 mg/día que contiene una dieta normal americana) no consiguió reducir los niveles plasmáticos de estos ácidos grasos ni alterar el curso clínico de la enfermedad14.\n\nEn 1986, Rizzo et al15 demostraron que añadiendo ácido oleico al medio de cultivo de fibroblastos de la piel de pacientes con ALD conseguía reducir de forma notable los niveles de C26:0. Estos autores concluyeron que los ácidos grasos monoinsaturados compiten con los saturados por el sistema de elongación de los ácidos grasos. Este hallazgo llevó al diseño de una nueva dieta, que combina la administración de glicerol trioleato (GTO), que contiene un 90 % de ácidos grasos en forma de ácido oleico y sólo trazas de ácidos grasos poliinsaturados de cadena muy larga), con la restricción dietética de AGCML saturados16, 17. Los pacientes recibieron aproximadamente un 25 % del valor calórico total (VCT) de la dieta en forma de GTO (45-90 ml/día). La dieta era realizable por la mayoría de los pacientes, y como efectos secundarios más frecuentes se encontraron estreñimiento y náuseas tras tomar el aceite, que se solucionaron incrementando el consumo de fibra y utilizando el aceite en forma de emulsión. Esta dieta consiguió disminuir un 50 % los niveles plasmáticos de C26:0 a los 4 meses, y en mujeres heterocigotas consiguió su normalización. No obstante, en estudios prospectivos a un año de seguimiento no se ha podido demostrar una modificación del estado neurológico y funcional, aunque los estudios neurofisiológicos sí que demuestran una discreta mejoría de la función nerviosa periférica. Los pacientes con la forma cerebral rápidamente progresiva sufren la enfermedad de forma inalterable.\n\nEl ácido erúcico (ácido cis-13-docosanoico) se halla presente en aceites vegetales derivados de la colza y la mostaza. Los pacientes con ALD no pueden metabolizar este ácido graso, y por este motivo se propuso como base del tratamiento con un preparado en forma de aceite que contiene gliceril trioleato y gliceril trierucato (GTE, que contiene un 95 % de ácido erúcico), en una proporción de 4:1 de GTO y GTE, llamado aceite de Lorenzo18. Este aceite tiene un poderoso efecto sobre los niveles de AGCML saturados en plasma, normalizando los niveles de C26:0 en 4 semanas de tratamiento, y con muy pocos efectos secundarios.\n\nEl régimen dietético que incluye el aceite de Lorenzo representa una modificación de la dieta GTO (tabla 2). En el caso de que los requerimientos energéticos no queden cubiertos con la dieta restringida en grasas y el aceite de Lorenzo, se puede incluir glucosa o polímeros de glucosa.\n\nLa mayoría de los pacientes que siguen la dieta del aceite de Lorenzo consiguen normalizar los niveles de C26:0 en plasma y en los hematíes19. La microviscosi-\n\n| Tabla 2. Dieta inicialmente descrita que incluye el aceite de Lorenzo como base fundamental del aporte lipídico de la dieta. |\n|---------------------------------------------------------------------------------------------------------------------------|\n| Dieta aceite de Lorenzo |\n| · Muy bajo contenido en AGCML saturados |\n| · 10 % del VCT en forma de grasa |\n| · Aceite de Lorenzo proporciona un 20 % del VCT (2-3 ml/kg/día) |\n| · Aceite de girasol para garantizar un aporte de ácido linoleico (5% VCT) |\n| · Cápsulas de aceite de pescado para proporcionar 240 mg de docosahexaenoico (C22:6) y 360 mg de eicosapentanoico (C22:5) |\n| · Polivitamínico y suplemento de minerales dependiendo de la edad |\n\nAGCML: grasos de cadena muy larga; VCT: valor caló\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ALD<|>EVENT<|>Adrenoleukodystrophy (ALD) is a genetic disorder that affects the metabolism of certain fatty acids, leading to the accumulation of very long-chain fatty acids in the body.)\n##\n(\"entity\"<|>RIZZO ET AL<|>PERSON<|>Rizzo et al are researchers who demonstrated the effects of oleic acid on fibroblasts from patients with ALD in 1986.)\n##\n(\"entity\"<|>GTO<|>ORGANIZATION<|>Glycerol trioleate (GTO) is a dietary supplement used in the treatment of ALD, containing 90% oleic acid.)\n##\n(\"entity\"<|>GTE<|>ORGANIZATION<|>Glycerol trierucate (GTE) is a dietary supplement containing 95% erucic acid, used in conjunction with GTO for treating ALD.)\n##\n(\"entity\"<|>ACEITE DE LORENZO<|>ORGANIZATION<|>The Lorenzo's oil is a treatment for ALD that combines GTO and GTE to normalize levels of C26:0 in patients.)\n##\n(\"entity\"<|>C26:0<|>ORGANIZATION<|>C26:0, or hexacosanoic acid, is a very long-chain fatty acid that accumulates in patients with ALD.)\n##\n(\"relationship\"<|>RIZZO ET AL<|>ALD<|>Rizzo et al conducted studies that contributed to understanding the dietary management of ALD<|>7)\n##\n(\"relationship\"<|>GTO<|>ALD<|>GTO is used as a dietary treatment to manage the levels of fatty acids in patients with ALD<|>8)\n##\n(\"relationship\"<|>GTE<|>ALD<|>GTE is used in the treatment of ALD to help normalize fatty acid levels<|>8)\n##\n(\"relationship\"<|>ACEITE DE LORENZO<|>ALD<|>Lorenzo's oil is a treatment specifically designed to manage ALD by normalizing C26:0 levels<|>9)\n##\n(\"relationship\"<|>C26:0<|>ALD<|>C26:0 is the fatty acid that accumulates in patients with ALD, indicating the severity of the condition<|>10)\n##\n(\"relationship\"<|>GTO<|>ACEITE DE LORENZO<|>GTO is a component of Lorenzo's oil, which is used to treat ALD<|>8)\n##\n(\"relationship\"<|>GTE<|>ACEITE DE LORENZO<|>GTE is another component of Lorenzo's oil, enhancing its effectiveness in treating ALD<|>8)\n<|COMPLETE|>"}]}